SGS Life Science to Expand Shanghai Facility
News Aug 04, 2014
The company will offer new services from the facility, including a new biotechnology laboratory for cytotoxicity testing, cell-based assays, plus endotoxin and ELISA testing. The current 1500 square meter facility provides services for method development and validation, testing of raw materials, APIs and finished products, as well as testing of Traditional Chinese Medicines.
The expansion program, which is due to commence in August 2014, will also see the introduction of packaging testing, including extractables and leachables, while an inductively coupled plasma mass spectrometer, for USP <233> Elemental Impurities, will also be located within the laboratory. Other new capabilities at the Shanghai site will include a dissolution lab for generic drug stability studies, a mycoplasma lab focused on the biological market, and a highly active compound (HAC) testing laboratory to meet growing market demand. In addition to new office space, a drug compatibility study lab, designed to meet regulatory requirements, will also be introduced.
“The investment in the Shanghai facility, and the increased and enhanced service offerings that will result, are essential to our continued expansion in China,” commented Andy Yi, General Manager, SGS Life Science Services, Shanghai. He added, “Much of the work that we undertake is on behalf of major multinational customers who demand that their drug and medical device products are subject to the same level of compliance and scrutiny that they would be if they had been manufactured in the West. This expansion will further serve the quality requirements of those customers.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018